Legend Biotech → Janssen (Johnson & Johnson)
Approved as Carvykti in 2022; Legend has collected the upfront and a steady run of milestones, more than the risk-adjusted value at signing.
The money
- Pre
- P12017
- P2
- P3now
- Filed
- Appr.
How to read these figures
Median upfront share of the 19 deals signed at Phase 1: 5.3%.
The risk-adjusted value weights the milestones by published success rates (5% chance of approval from Phase 1), with an assumed split between development and sales milestones. It is a model, not a reported figure.
Stage bar: the year marks the stage at signing, the orange step the stage reached today.
Territory: Worldwide collaboration (different profit split in Greater China and the rest of the world).
Comparable deals: 13 at Phase 1, oncology
This upfront, $350M, ranks 2 of 14. Median $66.5M, from $7.5M to $588M.
The 7 smaller ones are in the terminal. Same area and same stage at signing, tracked deals only: a short list, not a benchmark.
rNPV calculator: your assumptions
The drug
- CAR-T
- BCMA
- oncology
- Multiple myeloma
Market context: 1 of 1 disease
Multiple myeloma. 196,157 new cases a year (World, 2024; International Agency for Research on Cancer).
Already sold in it: Darzalex $14.35B, Carvykti $1.89B. Reported 2025 sales, worldwide, all uses of each medicine.
Patient counts and reported sales from public documents. Context, not a market size.
No other tracked deal shares this target (50 deals tracked).
Outside the tracker: 4 on TNFRSF17
- ELRANATAMABPhase 4Antibody
- IDECABTAGENE VICLEUCELApprovedGene
- TECLISTAMABPhase 4Antibody
- BELANTAMAB MAFODOTINWithdrawnAntibody drug conjugate
Open Targets, release 26.09, read 2026-11-17. Highest stage in any indication. A secondary source: recent or China-only programmes can be missing.
The trials
- 15
- registered
- 10
- running
- 2
- completed
- 1
- stopped
9 started by Janssen (Johnson & Johnson) since signing, the first after 6 months (NCT03548207). Registry status only, no results.
Most studied conditions
- Multiple Myeloma · 14
- Smoldering Multiple Myeloma · 1
- Extramedullary Myeloma · 1
Why a trial stopped
“The study was terminated early due to a strategic realignment of the sponsor's business plan, not related to safety, efficacy, or data integrity concerns.” NCT03758417
The sponsor's own words in the registry.
Results posted: 3 trials
NCT03548207 · Janssen Research & Development, LLC · posted 2024-04-02
Primary outcome, count of participants: Phase 1b: Number of Participants With Adverse Events as Per Severity
- Phase 1b (US Population): 0 Participants
Serious adverse events: Phase 1b (US Population): 11 of 29 (38%) · Phase 2 (US Population): 42 of 68 (62%) · Phase 2 (Japan Population): 1 of 9 (11%).
NCT04181827 · Janssen Research & Development, LLC · posted 2025-05-20
Primary outcome, median: Progression Free Survival (PFS)
- Arm A: Standard Therapy: PVd or DPd: 11.79 months (9.66 to 14.00)
- Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]): not estimable (NA in the registry)
Serious adverse events: Arm A: Standard Therapy: PVd or DPd: 98 of 208 (47%) · Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel]): 98 of 208 (47%).
NCT05347485 · Janssen Scientific Affairs, LLC · posted 2024-12-27
Primary outcome, number: Overall Response Rate (ORR)
- Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS): 57.3 Percentage of participants (45.9 to 68.2)
Serious adverse events: Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS): 42 of 82 (51%).
Copied from the registry as the sponsor posted them: efficacy and safety of these trials only, not compared across trials, not a verdict.
Points to check · 0
None of the automatic checks is triggered.
The parties
- 2%
- upfront vs buyer's cash
- 4%
- vs buyer's yearly R&D
Company profiles
Legend Biotech. 1 tracked deal, $1.70B announced, 0 ended or cut back. Own trials: 60% in oncology, of 10 as lead sponsor. Profile →
Janssen (Johnson & Johnson). 1 tracked deal, $1.70B announced, 0 ended or cut back. Own trials: 21% in oncology, of 1422 as lead sponsor. Profile →
Own trials: ClinicalTrials.gov, read 2026-11-17. Tracked deals only.
Sources
Janssen (Johnson & Johnson): last annual report filed before signing (10-K, 2017).
No share price series for Legend Biotech.
Deal file: SEC filings: 2, company releases: 2. Figures pending review.
